Oncotelic Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Oncotelic Therapeutics Inc 's ROA in the second quarter of 2026?
Oncotelic Therapeutics Inc achieved a return on average assets (ROA) of 81.75 % in its second quarter of 2026, this is above OTLC's average return on assets of -66.5%.
Oncotelic Therapeutics Inc assets over the 12 months ending in its second quarter of 2026 are valued at $302 million

ROA fell compared to the first quarter of 2026, despite the net income growth of % from the first quarter of 2026.

However, within the Healthcare sector 11 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 29 to 32.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	1379.53 %	1377.25 %	1373.49 %	5.13 %	-10.87 %
Y / Y Net Income Change	62.04 %	-	-	-	-
Net Income (TTM) in million	247	247	249	-2	-4
Return On Assets (TTM)	81.75 %	117.43 %	209.88 %	-7.11 %	-15.65 %
OTLC's Total Ranking	# 32	# 29	# 3162	# 3464	# 3551
Total Assets (TTM) in million	395	394	393	28	27
Seq. Total Assets Change	0.2 %	0.22 %	1296.1 %	5.53 %	0.05 %
Seq. Net Income Change	-	-	-	-	-

OTLC's 5 Years Annual ROA >> Back to OTLC Management Effectiveness >> Compare OTLC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 6
Sector	# 12
Overall	# 43

Return On Assets Statistics
High	Average	Low
209.88 %	-66.5 %	-407.17 %
(Dec 31 2025)		(Jun 30 2018)

Financial Statements
Oncotelic Therapeutics Inc 's Assets	$ 395 million	OTLC's Balance sheet
Oncotelic Therapeutics Inc 's Income	$ 0 million	Quarterly OTLC's Income Statement
OTLC's Income by Division		See OTLC's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	1373.49 %	-11.12 %	-16.89 %	52.95 %	-0.21 %
Total Assets in million	393	27	30	36	24
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	249	-5	-8	5	-11
Annual Return On Assets	63.35 %	-17.92 %	-27.34 %	12.95 %	-44.54 %

OTLC's 5 Years Annual ROA >> Back to OTLC Management Effectiveness >> Compare OTLC ROA to its Competitors

Comment on OTLC's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 63.35 % compared to prior year, due to annual net income growth of % to $249.02 million, while value of Oncotelic Therapeutics Inc 's overall assets grew just by 1373.49 % to $393.09 million, compared to $393.09 a year before.

More Return On Assets Ratios
OTLC's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
OTLC's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for OTLC's Competitors
Subscribers only: Roa for Oncotelic Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for OTLC's Customers

You may also want to know
OTLC's Roi	OTLC's Inventory Turnover Ratio	OTLC's Growth Rates	OTLC's Dividend Comparisons
	OTLC's Profitability Ratios	OTLC's Asset Turnover Ratio	OTLC's Dividend Growth
OTLC's Roe	OTLC's Valuation Ratios	OTLC's Financial Strength Ratios	OTLC's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Kyntra Bio Inc	156.80 %
Vor Biopharma Inc	154.23 %
Glucotrack Inc	151.40 %
Capforce Inc	141.40 %
Protagenic Therapeutics Inc new	137.58 %
Elutia Inc	108.72 %
Silexion Therapeutics Corp	99.09 %
Arbutus Biopharma Corp	96.04 %
Pulmatrix Inc	94.81 %
Quince Therapeutics Inc	88.46 %
Interpace Biosciences Inc	85.91 %
Oncotelic Therapeutics Inc	81.75 %
Rigel Pharmaceuticals Inc	72.27 %
Actinium Pharmaceuticals Inc	71.73 %
Sanuwave Health Inc	71.60 %
Exelixis Inc	70.51 %
Rallybio Corporation	64.51 %
Oramed Pharmaceuticals Inc	64.18 %
Fortress Biotech Inc	60.88 %
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %

Date modified: 2026-09-02T17:58:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.